221 related articles for article (PubMed ID: 21600250)
1. Anti-tumor activity of liposome encapsulated fluoroorotic acid as a single agent and in combination with liposome irinotecan.
Riviere K; Kieler-Ferguson HM; Jerger K; Szoka FC
J Control Release; 2011 Aug; 153(3):288-96. PubMed ID: 21600250
[TBL] [Abstract][Full Text] [Related]
2. Liposome co-encapsulation of synergistic combination of irinotecan and doxorubicin for the treatment of intraperitoneally grown ovarian tumor xenograft.
Shaikh IM; Tan KB; Chaudhury A; Liu Y; Tan BJ; Tan BM; Chiu GN
J Control Release; 2013 Dec; 172(3):852-61. PubMed ID: 24459693
[TBL] [Abstract][Full Text] [Related]
3. Increased preclinical efficacy of irinotecan and floxuridine coencapsulated inside liposomes is associated with tumor delivery of synergistic drug ratios.
Harasym TO; Tardi PG; Harasym NL; Harvie P; Johnstone SA; Mayer LD
Oncol Res; 2007; 16(8):361-74. PubMed ID: 17913044
[TBL] [Abstract][Full Text] [Related]
4. Effective co-encapsulation of doxorubicin and irinotecan for synergistic therapy using liposomes prepared with triethylammonium sucrose octasulfate as drug trapping agent.
Liu J; Chi D; Pan S; Zhao L; Wang X; Wang D; Wang Y
Int J Pharm; 2019 Feb; 557():264-272. PubMed ID: 30599233
[TBL] [Abstract][Full Text] [Related]
5. The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models.
Na YS; Jung KA; Kim SM; Hong YS; Ryu MH; Jang SJ; Moon DH; Cho DH; Kim JC; Lee JS; Kim TW
Cancer Chemother Pharmacol; 2011 Aug; 68(2):389-98. PubMed ID: 21046105
[TBL] [Abstract][Full Text] [Related]
6. Encapsulation, controlled release, and antitumor efficacy of cisplatin delivered in liposomes composed of sterol-modified phospholipids.
Kieler-Ferguson HM; Chan D; Sockolosky J; Finney L; Maxey E; Vogt S; Szoka FC
Eur J Pharm Sci; 2017 May; 103():85-93. PubMed ID: 28263913
[TBL] [Abstract][Full Text] [Related]
7. Development and evaluation of oxaliplatin and irinotecan co-loaded liposomes for enhanced colorectal cancer therapy.
Zhang B; Wang T; Yang S; Xiao Y; Song Y; Zhang N; Garg S
J Control Release; 2016 Sep; 238():10-21. PubMed ID: 27432750
[TBL] [Abstract][Full Text] [Related]
8. pH-responsive and folate-coated liposomes encapsulating irinotecan as an alternative to improve efficacy of colorectal cancer treatment.
Nunes SS; Miranda SEM; de Oliveira Silva J; Fernandes RS; de Alcântara Lemos J; de Aguiar Ferreira C; Townsend DM; Cassali GD; Oliveira MC; Branco de Barros AL
Biomed Pharmacother; 2021 Dec; 144():112317. PubMed ID: 34634556
[TBL] [Abstract][Full Text] [Related]
9. Irinotecan and 5-fluorouracil-co-loaded, hyaluronic acid-modified layer-by-layer nanoparticles for targeted gastric carcinoma therapy.
Gao Z; Li Z; Yan J; Wang P
Drug Des Devel Ther; 2017; 11():2595-2604. PubMed ID: 28919710
[TBL] [Abstract][Full Text] [Related]
10. Irinophore C™, a lipid-based nanoparticulate formulation of irinotecan, is more effective than free irinotecan when used to treat an orthotopic glioblastoma model.
Verreault M; Strutt D; Masin D; Anantha M; Waterhouse D; Yapp DT; Bally MB
J Control Release; 2012 Feb; 158(1):34-43. PubMed ID: 22001870
[TBL] [Abstract][Full Text] [Related]
11. Determination of an optimal dosing schedule for combining Irinophore C™ and temozolomide in an orthotopic model of glioblastoma.
Verreault M; Wehbe M; Strutt D; Masin D; Anantha M; Walker D; Chu F; Backstrom I; Kalra J; Waterhouse D; Yapp DT; Bally MB
J Control Release; 2015 Dec; 220(Pt A):348-357. PubMed ID: 26528901
[TBL] [Abstract][Full Text] [Related]
12. Double-crosslinked nanocomposite hydrogels for temporal control of drug dosing in combination therapy.
Wu C; Liu J; Zhai Z; Yang L; Tang X; Zhao L; Xu K; Zhong W
Acta Biomater; 2020 Apr; 106():278-288. PubMed ID: 32084599
[TBL] [Abstract][Full Text] [Related]
13. Liposome formulation of a novel hydrophobic aryl-imidazole compound for anti-cancer therapy.
Liu J; Lee H; Huesca M; Young A; Allen C
Cancer Chemother Pharmacol; 2006 Sep; 58(3):306-18. PubMed ID: 16333677
[TBL] [Abstract][Full Text] [Related]
14. The Effect of Phase Transition Temperature on Therapeutic Efficacy of Liposomal Bortezomib.
Korani M; Nikoofal-Sahlabadi S; Nikpoor AR; Ghaffari S; Attar H; Mashreghi M; Jaafari MR
Anticancer Agents Med Chem; 2020; 20(6):700-708. PubMed ID: 31893998
[TBL] [Abstract][Full Text] [Related]
15. Novel sulfobutyl ether cyclodextrin gradient leads to highly active liposomal irinotecan formulation.
Li C; Cui J; Wang C; Li Y; Zhang L; Xiu X; Li Y; Wei N; Zhang L; Wang P
J Pharm Pharmacol; 2011 Jun; 63(6):765-73. PubMed ID: 21585373
[TBL] [Abstract][Full Text] [Related]
16. Novel lipophilic SN38 prodrug forming stable liposomes for colorectal carcinoma therapy.
Xing J; Zhang X; Wang Z; Zhang H; Chen P; Zhou G; Sun C; Gu N; Ji M
Int J Nanomedicine; 2019; 14():5201-5213. PubMed ID: 31371956
[No Abstract] [Full Text] [Related]
17. Dual-effect liposomes encapsulated with doxorubicin and chlorin e6 augment the therapeutic effect of tumor treatment.
Peng PC; Hong RL; Tsai YJ; Li PT; Tsai T; Chen CT
Lasers Surg Med; 2015 Jan; 47(1):77-87. PubMed ID: 25559348
[TBL] [Abstract][Full Text] [Related]
18. Encapsulation of the topoisomerase I inhibitor GL147211C in pegylated (STEALTH) liposomes: pharmacokinetics and antitumor activity in HT29 colon tumor xenografts.
Colbern GT; Dykes DJ; Engbers C; Musterer R; Hiller A; Pegg E; Saville R; Weng S; Luzzio M; Uster P; Amantea M; Working PK
Clin Cancer Res; 1998 Dec; 4(12):3077-82. PubMed ID: 9865923
[TBL] [Abstract][Full Text] [Related]
19. A combination of liposomal sunitinib plus liposomal irinotecan and liposome co-loaded with two drugs enhanced antitumor activity in PC12-bearing mouse.
Maitani Y; Saito H; Seishi Y; Iwase Y; Yamauchi T; Higashiyama K; Sugino T
J Drug Target; 2012 Dec; 20(10):873-82. PubMed ID: 23050928
[TBL] [Abstract][Full Text] [Related]
20. The influence of trapping agents on the antitumor efficacy of irinotecan liposomes: head-to-head comparison of ammonium sulfate, sulfobutylether-β-cyclodextrin and sucrose octasulfate.
Yang W; Yang Z; Fu J; Guo M; Sun B; Wei W; Liu D; Liu H
Biomater Sci; 2018 Dec; 7(1):419-428. PubMed ID: 30500018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]